Several ASX healthcare companies are leading the charge in finding new treatments for complex neurological disorders.

Neurizon Therapeutics (ASX:NUZ) has shared an update on its preparations for its HEALEY ALS Platform Trial – a multicentre, ...

Neurizon Therapeutics (ASX:NUZ) plans to implement several initiatives to get the clinical hold lifted of its IND application ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company ...

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Neurizon Therapeutics Limited (NUZ). However, you won't necessarily see their names in the ...

Neurizon Therapeutics has submitted a formal request to the US FDA for advice on pharmacokinetic studies needed to lift hold on its IND application for NUZ-001 Neurizon Therapeutics (ASX ...

In contrast, broker Morgans is ultra bullish about Neurizon Therapeutics (ASX:NUZ) as the company seeks to get its ...

ByInvesting.com • Dec 18, 2024 Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study Highlights:Positive preclinical results in human in vitro iPSC Motor ...

Neurizon Therapeutics (ASX: NUZ) announced last month that the regulator had requested additional animal exposure data be provided to assess adequacy of systemic exposure to NUZ-001 during the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Followed categories will be added to My News. Neurizon Therapeutics (ASX: NUZ) announced last month that the regulator had requested additional animal exposure data be provided to assess adequacy ...